Key Highlights for Investors

• Strategic Transformation: SDAI Limited is accelerating its transformation into a biotechnology company with the launch of its proprietary plant stem cell skincare line, Bluecode Biotech B-III Series.
• Milestone Product Launch: The B-III Series will debut concurrently in Singapore and China on 21 December 2025, marking a significant pivot in the Group’s business strategy.
• Innovative Product Line-Up: The new series is comprised of three advanced skincare products, each leveraging plant stem cell and bioengineering technologies to target anti-aging and cellular rejuvenation.
• Revenue Diversification & Growth Prospects: The move is expected to tap into high-growth anti-aging and biotechnology sectors, potentially opening up substantial new revenue streams and strengthening long-term growth.
• Market Distribution: Products will be distributed primarily through leading e-commerce platforms to maximize market reach and accessibility.
• Leadership Commitment: Executive Chairperson Madam Hao Dongting emphasized the Group’s determination to create sustainable value for shareholders and establish SDAI as a leader in biotechnology.

In-Depth Overview

SDAI Limited, listed on the Catalist Board of the Singapore Exchange, has announced a landmark development in its strategic transformation. The Group will officially launch its proprietary plant stem cell skincare line, Bluecode Biotech B-III Series, on 21 December 2025. This launch represents a critical step in SDAI’s initiative to diversify from its traditional businesses and establish itself as a prominent player in the biotechnology and healthcare market.

Details of the Bluecode Biotech B-III Skincare Series

• Singapore Launch: The first product to debut in Singapore will be the Photoprotective Bio Facial Mist (抗光损喷雾), setting the stage for the Group’s entry into the skincare market with a high-tech, plant stem cell-based formula.
• China Launch: The China market will see the simultaneous roll-out of three products:
  • Apple Fruit Cell Serum (苹果果实细胞精华液)
  • Photoprotective Bio Facial Mist (抗光损喷雾)
  • Adenium Obesum Cell Facial Mask (沙漠蔷薇叶细胞面膜)
• Distribution Channels: The B-III Series will be available via established e-commerce platforms, targeting rapid adoption and consumer accessibility in both markets.

Biotechnology Innovation and Product Features

• Apple Fruit Cell Serum: Utilizes extracts from Uttwiler Spätlauber apple stem cells, a Swiss variety renowned for regenerative qualities, aiming to activate the skin’s natural self-repair mechanisms.
• Photoprotective Bio Facial Mist: Employs light-filtering and barrier-support technologies for topical application, notably formulated without conventional sunscreen ingredients.
• Adenium Obesum Cell Facial Mask: Incorporates nano-emulsion delivery technology, highland gentian root extract, ectoine, and ergothioneine to soothe, restore, and strengthen photodamaged skin.

Potential Price-Sensitive Developments

• Strategic Transformation: The shift towards biotechnology and healthcare products is a major pivot for SDAI Limited, signaling a commitment to enter high-growth markets and diversify beyond existing business lines. Such structural changes are often closely watched by investors as they can significantly impact valuation and long-term prospects.
• First-Mover Advantage: The simultaneous market entry in Singapore and China positions SDAI to capture market share in two of Asia’s most important consumer markets for anti-aging and skincare products.
• Pipeline and R&D Capabilities: SDAI’s ability to leverage in-house research and development for advanced bioengineering and plant stem cell technology could provide a sustainable competitive edge, supporting future product innovation and growth.
• Potential Revenue Impact: Successful commercialization of the B-III Series could have a material positive effect on SDAI’s revenue streams, profitability, and ultimately, shareholder value.
• Leadership Endorsement: The Executive Chairperson’s strong statements underscore management’s confidence in the Group’s strategic direction and capacity to deliver value, which may influence investor sentiment positively.

Company Outlook and Commitment

The Group’s entry into the biotechnology sector is designed to unlock new growth opportunities, diversify revenue, and enhance long-term shareholder value. SDAI has articulated a clear plan to integrate biotechnology across the medical, skincare, and health product industries, signaling an ambition to become a leading force in the sector.

The successful rollout of the Bluecode Biotech B-III skincare series is projected to be a major milestone in this journey, with management reaffirming its commitment to maximizing shareholder value through breakthrough advancements in cellular rejuvenation.

Investors should closely monitor the market reception of the B-III Series, future product developments, and SDAI’s ongoing execution of its biotechnology-centric growth strategy, as these factors may be material to the company’s valuation and share price performance going forward.

Contact and Further Information

For more details, visit www.sdai.com.sg or contact the company’s appointed media representative.
Contact Person: Yong Jing Wen, Woodnote Consulting
Email: [email protected]
Phone: (65) 9860 3047

Disclaimer

This article is for informational purposes only and does not constitute investment advice or an offer to buy or sell any securities. Prospective investors should conduct their own due diligence and consult their financial advisors before making any investment decisions. The Singapore Exchange Securities Trading Limited assumes no responsibility for the content of this report.

View SDAI Historical chart here